

Global Osteoarthritis Pain Market 2016 Share, Trend, Segmentation and Forecast to 2020

Wiseguyreports.com add report on "Global Osteoarthritis Pain Market 2016-2020" to its research database.

PUNE, INDIA, May 30, 2016 /EINPresswire.com/ -- About the [Osteoarthritis Pain](#) Drugs Market Osteoarthritis, the most common type of arthritis, is a leading cause of disability. It is a chronic, progressive degenerative joint disease, which is characterized by gradual destruction of the articular cartilage, hypertrophy of the bone margins, and a series of biochemical and morphological changes in the synovial membrane and joint capsule. This results in pain and loss of movement. It is also known as degenerative joint disease, hypertrophic arthritis, and degenerative arthritis, and is most commonly prevalent in older (above 60 years of age) and middle-aged people (between 40-59 years of age). The exact etiology of osteoarthritis is not well understood, but is believed to be an outcome of mechanical and molecular events in the affected joint. Increasing age, obesity, overuse of the joint, weak thigh muscles, and genetics are some of the common risk factors. Treatment is given depending upon the affected joint, including the hand, wrist, neck, back, knee, and hip, and involves medication and exercise.

Technavio's analysts forecast the global osteoarthritis pain drugs market to grow at a CAGR of 8.38% during the period 2016-2020.

Complete report details @ <https://www.wiseguyreports.com/reports/global-osteoarthritis-pain-market-2016-2020> □

Covered in this report

The report covers the present scenario and the growth prospects of the global osteoarthritis pain drugs market for 2016-2020. To calculate the market size, the report considers revenue generated from the sales of branded, generic, and off-label drugs used to treat osteoarthritis pain. It also considers the revenues to be generated from the sales of drugs that are expected to be launched into the market.

The market is divided into the following segments based on geography:

- Americas
- APAC
- EMEA

The report, Global Osteoarthritis Pain Drugs Market 2016-2020, has been prepared based on an in-depth market analysis with inputs from industry experts. The report covers the market



landscape and its growth prospects over the coming years. The report also includes a discussion of the key vendors operating in this market.

Key vendors

- Abbott Laboratories
- Johnson & Johnson
- Novartis International
- Pfizer

Request a sample report @ <https://www.wiseguyreports.com/sample-request/global-osteoarthritis-pain-market-2016-2020>

Other prominent vendors

- AbbVie
- Abiogen Pharma
- Afferent Pharmaceuticals
- Astellas Pharma
- BioDelivery Sciences International
- Crystal Genomics
- Cytori Therapeutics
- Daiichi Sankyo
- Eli Lilly
- Endo Pharmaceuticals Holdings
- Horizon Pharma
- iCeutica
- Iroko Pharmaceuticals
- Merck
- Nuvo Research
- Regeneron Pharmaceuticals
- Sanofi
- SantoSolve
- Techfields Pharma
- Winston Pharmaceuticals
- Yooyoung Pharmaceutical
- Zynerba Pharmaceuticals

Market driver

- Significant unmet medical needs
- For a full, detailed list, view our report

Market challenge

- Preference for alternative therapies
- For a full, detailed list, view our report

Market trend

- Emergence of new treatments
- For a full, detailed list, view our report

Key questions answered in this report

- What will the market size be in 2020 and what will the growth rate be?
- What are the key market trends?
- What is driving this market?
- What are the challenges to market growth?
- Who are the key vendors in this market space?
- What are the market opportunities and threats faced by the key vendors?
- What are the strengths and weaknesses of the key vendors?

Make an enquiry before buying this Report @ <https://www.wiseguyreports.com/enquiry/global-osteoarthritis-pain-market-2016-2020>

Table of content

PART 01: Executive summary

- Highlights

PART 02: Scope of the report

- Market overview
- Assumptions
- Top-vendor offerings

PART 03: Market research methodology

- Research methodology
- Economic indicators

PART 04: Introduction

- Key market highlights
- Key buying criteria

PART 05: Disease overview

- Understanding osteoarthritis
- Etiology and pathophysiology
- Risk factors
- Signs and symptoms
- Diagnosis
- Disease management
- Surgical treatment
- Epidemiology
- Economic burden of osteoarthritis

PART 06: Pipeline portfolio

- Information on pipeline candidates
- Ampion
- Tanezumab
- Zilretta (FX006)
- Fasinumab
- IP 880
- SoluMatrix Naproxen
- ABT-981
- AF-219
- ASP7962

PART 07: Osteoarthritis pain drugs: Clinical trials

PART 08: Opportunities for research in osteoarthritis

- Gaps between current research and possible research issues
- Challenges for vendors involved in osteoarthritis drug development

PART 09: Market landscape

- Market overview
- Market size and forecast
- Five forces analysis

PART 10: Market segmentation by drug class

- NSAIDs
- Opioids
- Viscosupplements
- Corticosteroids
- Others
- Global NSAIDs market
- Global opioids market
- Global viscosupplements market
- Global corticosteroids market

PART 11: Market segmentation by ROA

- Oral
- Parenteral
- Topical

PART 12: Market segmentation by dosage form

- Solid
- Liquid
- Semi-solid

PART 13: Geographical segmentation

- Osteoarthritis pain drugs market in Americas
- Osteoarthritis pain drugs market in US
- Osteoarthritis pain drugs market in EMEA
- Osteoarthritis pain drugs market in APAC

PART 14: Market drivers

- Significant unmet medical needs
- Promising drug pipeline
- Increase in prevalence of osteoarthritis and obesity

PART 15: Impact of drivers

PART 16: Market challenges

- Preference for alternative therapies
- Loss of patent exclusivity of branded therapies
- Adverse effects of drugs

PART 17: Impact of drivers and challenges

PART 18: Market trends

- Emergence of new treatments
- Use of off-label drugs
- Strategic alliances

PART 19: Vendor landscape

- Competitive scenario
- Abbott Laboratories
- Johnson & Johnson
- Novartis
- Pfizer
- Other prominent vendors

PART 20: Upcoming vendors with novel approaches

- Ampio Pharmaceuticals
- Flexion Therapeutics
- Kitov Pharmaceuticals

PART 21: Appendix

- List of abbreviations

Buy this report @ https://www.wiseguyreports.com/checkout?currency=one_user-USD&report_id=477487

Norah Trent
WiseGuy Research Consultants Pvt. Ltd.
16468459349
[email us here](#)

This press release can be viewed online at: <http://www.einpresswire.com>

Disclaimer: If you have any questions regarding information in this press release please contact the company listed in the press release. Please do not contact EIN Presswire. We will be unable to assist you with your inquiry. EIN Presswire disclaims any content contained in these releases. © 1995-2019 IPD Group, Inc. All Right Reserved.